APA (7th ed.) Citation

Wu, Y., Amonkar, M. M., Sherrill, B. H., O’Shaughnessy, J., Ellis, C., Baselga, J., . . . Burstein, H. J. (2011). Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Annals of Oncology, 22(12), 2582. https://doi.org/10.1093/annonc/mdr014

Chicago Style (17th ed.) Citation

Wu, Y., M. M. Amonkar, B. H. Sherrill, J. O’Shaughnessy, C. Ellis, J. Baselga, K. L. Blackwell, and H. J. Burstein. "Impact of Lapatinib Plus Trastuzumab Versus Single-agent Lapatinib on Quality of Life of Patients with Trastuzumab-refractory HER2+ Metastatic Breast Cancer." Annals of Oncology 22, no. 12 (2011): 2582. https://doi.org/10.1093/annonc/mdr014.

MLA (9th ed.) Citation

Wu, Y., et al. "Impact of Lapatinib Plus Trastuzumab Versus Single-agent Lapatinib on Quality of Life of Patients with Trastuzumab-refractory HER2+ Metastatic Breast Cancer." Annals of Oncology, vol. 22, no. 12, 2011, p. 2582, https://doi.org/10.1093/annonc/mdr014.